Featured Experience:

• Advised OmniaBio in connection with its launch, including its spinout from the Centre for Commercialization of Regenerative Medicine (CCRM), its C$30 million sale of a 39% interest to Medipost Co., C$40 million in government funding by the Government of Ontario, and up to C$100 million convertible note financing and the negotiation of its new C$580 million cell and gene therapy facility.
• Advised Thornhill Medical in negotiating manufacturing and supply agreements to make and deliver mobile compact ventilator systems as part of the Canadian government's response to fight COVID-19.
• Represented 7D Surgical, a medical device company developing advanced optical and machine-vision technologies for surgical navigation, in its $110 million sale to SeaSpine Holdings Corporation, a global medical technology company developing surgical solutions for the treatment of spinal disorders.

Transactional and Investment Matters:

• Represented Triumvira Immunologics, a biotechnology company developing and commercializing novel cell therapies to treat cancer,
  • in its $55 million Series A financing led by Northpond Ventures and Leaps by Bayer, the impact investment unit of Bayer AG.
  • in its $45 million Series A financing extension, bringing the total round to approximately $100 million.
• Represented Conavi Medical in the $20 million financing of Novasight Hybrid System, an imaging platform to support minimally invasive heart procedures.
• Advised a digital wound care company Swift Medical
  • in its $35 million (C$44 million) Series B financing led by Virgo Investment Group LLC to incorporate artificial intelligence (AI) in wound care delivery.
  • in its $12 million Series A financing led by Data Collective.
• Represented 7D Surgical, a medical device company developing advanced optical and machine-vision technologies for surgical navigation,
  • in its $110 million sale to SeaSpine Holdings Corporation, a global medical technology company developing surgical solutions for the treatment of spinal disorders.
  • in multiple private placements to fund and support the commercial launch of its FDA 510(k) approved Machine-vision Image Guided Surgery (MvIGS) system.
• Advised Versant Ventures, OrbiMed, F-Prime Capital, and Sixty Degree Capital in the $80 million Series D financing of Turnstone Biologics Corp, a clinical-stage biotechnology company developing cancer immunotherapies.
• Advised OrbiMed
  • as the lead investor in the $41 million Series B financing of Turnstone Biologics Inc.
  • in a $135 million multi-series investment in Enobia Pharma Inc. (now Alexion Montréal Corp.).
• Advised OrbiMed and other investors in their investment in the $42 million Series C financing of Turnstone Biologics Inc.
• Represented Isologic Innovative Radiopharmaceuticals
  • in its acquisition of commercial distribution of diagnostic FDG (fluorodeoxyglucose) molecules from the Centre for Probe Development and Commercialization.
  • in its $10 million acquisition of the radiopharmacy division of Lantheus Medical Imaging, Inc.
• Advised Synaptive Medical
  • in a US$40 million investment by Export Development Canada.
  • in a $17 million preferred share investment by Sensegain Group, a leading asset management firm in China.
  • in its $25 million preferred share financing and concurrent C$50 million debt-to-equity conversion.
• Represented Northern Biologics
  • in the global sale of its lead asset, a clinical-stage immuno-oncology antibody, to a subsidiary of AstraZeneca plc.
  • in its sale of two immuno-oncology programs to Boehringer Ingelheim International GmbH.
• Represented Riot Games in its acquisition of computer game developer Hypixel Studios.
• Advised Hikma Ventures, the investment arm of Hikma Pharmaceuticals PLC, as the lead investor in Winterlight Labs Inc.'s C$5.6 million Series A financing.
• Represented MolecuLight,
  • in its financing transaction with BDC Capital and iGan Ventures.
  • in its US$10 million loan from SWK Holdings to support global commercial expansion.
  • in the sale of its clinical oncology business to photonamic GmbH & Co. KG.
  • in its $7.5 million loan from Oxford Finance to fund the expansion of Moleculight i:X, a portable device used to digitally measure bacteria in chronic wounds to optimize treatment.
• Advised Kalytera Therapeutics, a pioneer in next-generation cannabinoid therapeutics,
  • in its C$15 million multi-tranche private placement of common shares.
  • in its C$6.76 million public offering of units.
• Represented B. Braun Melsungen in its acquisition of a majority interest in Sterinova Inc., a drug delivery and medical device company.
• Represented Merus Labs in its C$342 million sale to Norgine B.V.
• Advised LEAGUE in its C$33 million Series A venture capital financing led by OMERS Ventures. The investment, one of the largest Series A financings in the Canadian tech industry, included Infinite Potential Technologies, Real Ventures, BDC IT Venture Fund, RBC, Manulife Financial, and Power Financial Corporation.
• Represented Cinven in its $3.5 billion (£2.3 billion) sale of Amdipharm Mercury Company Limited to Concordia Healthcare Corp.Represented Nordion in the $200 million sale of TheraSphere®, its targeted therapies division, to BTG plc.
• Advised Tandem Expansion Fund in its subscription in Blueprint Software Systems, Inc.'s private placement of Class B convertible preferred shares.

Other Experience:

• Advised Thornhill Medical in negotiating manufacturing and supply agreements to make and deliver mobile compact ventilator systems as part of the Canadian government's response to fight COVID-19.
• Advised OmniaBio in connection with its launch, including its spinout from the Centre for Commercialization of Regenerative Medicine (CCRM), its C$30 million sale of a 39% interest to Medipost Co., C$40 million in government funding by the Government of Ontario, and up to C$100 million convertible note financing and the negotiation of its new C$580 million cell and gene therapy facility.
• Advised Conavi Medical in its exclusive distribution agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Ltd. in connection with the sale of its Foresight™ Intracardiac Echocardiography (ICE) and Novasight™ Hybrid Intravascular Imaging systems in China, Hong Kong, Taiwan, and Macau.
• Advised Colibri Technologies (now Conavi Medical Inc.) in an exclusive distribution agreement with Japan Lifeline Co., Ltd. for the distribution of Colibri’s intracardiac echocardiography imaging system in Japan.